First-in-class exposure in man
First-in-class exposure in man
9 December 2010 at 11:00 AM EST
The first three patients with melanoma have completed dosing in the IMCgp100 phase I trial in the UK. Enrolment is now open for the second cohort in which patients will be given a higher dose, as planned. This is the first milestone in a dose-finding study in patients with advanced malignant melanoma, designed to establish a tolerability of increasing doses of IMCgp100. When this arm of the study is complete, a second phase is planned to assess the effect of the selected dose on pharmacodynamic markers when given repeatedly to a larger group of patients.
IMCgp100 is the first ImmTAC from Immunocore’s first-in-class technology platform to enter clinical trials.